Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus reuteri NCIMB 30242

What does the research say about Lactobacillus reuteri NCIMB 30242?

2 health outcomes synthesised

Lactobacillus reuteri NCIMB 30242 has been studied for 2 health outcomes, both related to cardiovascular risk factors. The strongest evidence area is for reduced blood cholesterol, supported by 3 studies, though the overall evidence strength is low due to the small number of studies. Research has primarily focused on hypercholesterolemic adults, with no consistent effective dose reported across studies.

Strongest evidence: No outcomes currently meet high or moderate evidence strength criteria. Both researched outcomes—reduced blood cholesterol and improved blood lipid profile—are evaluated as low evidence strength. For reduced blood cholesterol, all 3 studies (1 randomized controlled trial and 2 meta-analyses) reported beneficial effects, with one RCT showing a 9.14% reduction in total cholesterol (P<0.001). Effect sizes ranged from small to moderate. No consistent effective dose was reported.

Mixed or weaker evidence: Both outcomes are based on small evidence bases (3 studies each) and carry low evidence strength. For improved blood lipid profile, only 1 of 3 studies (a single RCT) reported statistically significant findings, with small effect sizes for reductions in LDL-C/HDL-C ratio and apoB-100/apoA-1 ratio. The remaining 2 studies were reviews that may overstate the effect.

Effective dose patterns: No cross-cutting dose insights emerged, as dosing was not consistently reported across studies—one study did not specify sample size or population details, and effective dose information is absent for both outcomes.

Population insights: The most studied population across both outcomes is hypercholesterolemic adults. One meta-analysis in the cholesterol outcome included general adult populations from multiple strains, limiting strain-specific conclusions.

Notable caveats: Both syntheses highlight a small evidence base (only 3 studies per outcome) and a strong risk of publication bias, as null-result studies are less likely to be published or indexed. For blood cholesterol, one study lacked sample size and population details. For blood lipid profile, the two reviews are not original research.

Frequently asked

  • What is Lactobacillus reuteri NCIMB 30242 good for according to research?
    Research on Lactobacillus reuteri NCIMB 30242 has focused on two cardiovascular-related outcomes: reducing blood cholesterol and improving blood lipid profile. All 3 studies on blood cholesterol reported beneficial effects, with one RCT showing a 9.14% reduction in total cholesterol. However, evidence strength is low for both outcomes due to the small number of studies.
  • What dose of Lactobacillus reuteri NCIMB 30242 is typically used in studies?
    No consistent effective dose was reported across the 3 studies for either outcome. Dosing was not consistently described, and one study did not specify dosing details at all. As a result, no dose range can be reliably attributed to this strain based on current research.
  • Who benefits most from Lactobacillus reuteri NCIMB 30242?
    The most studied population across both outcomes is hypercholesterolemic adults. One meta-analysis on blood cholesterol also included general adult populations, but findings may be confounded by multiple strains. Evidence is insufficient to identify other subgroups that might benefit.
  • Are there caveats or limitations in the research on Lactobacillus reuteri NCIMB 30242?
    Yes, both syntheses note that the evidence base is small (only 3 studies per outcome), making conclusions preliminary. Publication bias is a concern—null-result studies are less likely to be published. For blood cholesterol, one study lacked sample size and population details, and for blood lipid profile, two of three studies were reviews that may overstate effects.
  • Does Lactobacillus reuteri NCIMB 30242 help with reducing blood cholesterol?
    All 3 studies on blood cholesterol reported beneficial effects, with one RCT showing a statistically significant 9.14% reduction in total cholesterol. However, evidence strength is low, and the findings should be considered preliminary due to the small number of studies and potential publication bias.
  • Does Lactobacillus reuteri NCIMB 30242 help with improving blood lipid profile?
    All 3 studies reported beneficial effects on blood lipid profile, but only one was a randomized controlled trial that showed statistically significant improvements in LDL-C/HDL-C ratio and apoB-100/apoA-1 ratio with a small effect size. The other two studies are reviews, and the overall evidence strength is low.

Most-studied combinations with Lactobacillus reuteri NCIMB 30242

most supplement research is combination research
Also studied with:Lactobacillus fermentum CECT5716 (2)

  • FLORASSIST Probiotic Heart Health

    By Life Extension

    4.6 (406 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $24.00
    		In
    Vitacost
    $23.99
    		In
    Vitamin Shoppe
    $-
    		Out
Back to top